Telomir Pharmaceuticals, Inc. (TELO) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 17, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TELO SEC filings page.
This page shows Telomir Pharmaceuticals, Inc. (TELO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The numbers show a research-led company funded mainly by new capital, with spending and losses still ahead of operating cash generation.
The important earnings-quality gap is that FY2025's net loss was$10.4M , while operating cash outflow was$3.7M ; that divergence points to non-cash accounting items or accrual timing rather than equivalent cash consumption. SG&A reached$8.1M , more than three times the$2.4M R&D spend, indicating the cost base expanded beyond research alone.
In FY2025, financing supplied
The current ratio rose from 1.9x in FY2024 to 5.1x in FY2025, giving near-term assets more coverage over current obligations. Debt-to-equity fell from 1.1x to 0.2x, while the reported liquidity comparison equaled 23.7 months of latest annual operating outflow—a historical balance-to-outflow comparison, not a forecast.
Financial Health Signals
Telomir Pharmaceuticals, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Telomir Pharmaceuticals, Inc. passes 2 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 3 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Telomir Pharmaceuticals, Inc. reported a net loss of $10.4M while operations used $3.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Telomir Pharmaceuticals, Inc. reported -$1.7M in net income in Q2 2026. Against the prior quarter it is down 73.7%.
Telomir Pharmaceuticals, Inc. earned -$0.79 per diluted share (EPS) in Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
Telomir Pharmaceuticals, Inc. held $5.2M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Telomir Pharmaceuticals, Inc.'s ROE was -34.2% in Q2 2026, measuring profit generated per dollar of shareholder equity. Against the prior quarter it is down 14.2 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Telomir Pharmaceuticals, Inc. invested $445K in research and development in Q2 2026. This represents an increase of 938.0% from the same quarter a year earlier. Against the prior quarter it is down 4.9%.
Not reported for Q2 2026.
Not reported for Q2 2026.
TELO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $445K+938.0% | $468K+38.8% | N/A | $760K+21.1% | $43K-92.8% | $337K-58.1% | N/A | $627K+139.0% |
| SG&A Expenses | $1.3M | $574K-69.0% | N/A | $387K | N/A | $1.9M+149.6% | N/A | N/A |
| Operating Income | N/A | N/A | N/A | N/A | N/A | $2.2M+14.2% | N/A | N/A |
| Interest Expense | $3K+125.6% | $1K+2628.3% | N/A | N/A | $1K | $46-100.0% | N/A | N/A |
| Net Income | -$1.7M | -$991K+54.5% | N/A | -$1.1M | N/A | -$2.2M+65.1% | N/A | N/A |
| EPS (Basic) | -$0.79-364.7% | -$0.03+57.1% | -$0.06-105.9% | -$0.03+85.0% | -$0.17-440.0% | -$0.07+69.6% | $1.02+64.5% | -$0.20-233.3% |
| EPS (Diluted) | -$0.79 | -$0.03 | -$0.06-105.9% | -$0.03+85.0% | -$0.17-440.0% | -$0.07+69.6% | $1.02+64.5% | -$0.20-233.3% |
| Diluted Shares (Avg) | 61M | 34M | N/A | 32M+9.4% | 30M+1.4% | 30M+1.7% | N/A | 30M+9.3% |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA, Income Tax.
TELO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $5.4M+546.8% | $5.8M+1078.7% | $7.3M+454.5% | $7.4M+610.4% | $830K-60.5% | $491K-86.0% | $1.3M-72.3% | $1.0M |
| Current Assets | $5.4M+546.8% | $5.8M+1078.7% | $7.3M+454.5% | $7.4M+610.4% | $830K-60.5% | $491K-86.0% | $1.3M+204.2% | $1.0M |
| Cash & Equivalents | $5.2M+585.4% | $5.6M+1279.8% | $7.3M+475.5% | $7.3M+778.1% | $754K-60.0% | $403K-87.7% | $1.3M+102753.9% | $835K |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $332K-4.6% | $827K+26.8% | $1.4M+109.7% | $423K-29.5% | $348K-34.8% | $652K+34.1% | $681K-49.0% | $600K |
| Current Liabilities | $332K-4.6% | $827K+26.8% | $1.4M+109.7% | $423K-29.5% | $348K-34.8% | $652K+34.1% | $681K-49.0% | $600K |
| Non-Current Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Equity | $5.0M+946.0% | $5.0M+3180.1% | $5.9M+819.6% | $7.0M+1478.8% | $481K-70.4% | -$161K-105.3% | $643K-81.3% | $442K-79.7% |
| Retained Earnings | -$43.7M-15.5% | -$42.0M-28.1% | -$41.0M-34.0% | -$38.9M-40.6% | -$37.8M-73.9% | -$32.8M-61.3% | -$30.6M-117.6% | -$27.7M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
TELO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.0M-45.4% | -$1.8M-105.5% | -$1.2M-98.3% | -$927K+7.5% | -$696K+54.3% | -$863K+55.5% | -$606K+44.3% | -$1.0M+50.0% |
| Stock-Based Compensation | $199K-95.7% | $40K-97.1% | N/A | N/A | $4.7M | $1.4M | N/A | N/A |
| Financing Cash Flow | $622K | $47K | $1.2M+11.7% | $7.5M+16093.2% | N/A | N/A | $1.0M-4.5% | -$47K-102.4% |
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
TELO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -34.2% | -20.0% | N/A | -15.8% | N/A | N/A | N/A | N/A |
| Return on Assets | -32.1% | -17.1%+426.7pp | N/A | -14.9% | N/A | -443.8%-265.3pp | N/A | N/A |
| Current Ratio | 16.14+13.8x | 7.00+6.2x | 5.14+3.2x | 17.51+15.8x | 2.38-1.6x | 0.75-6.4x | 1.94+1.6x | 1.74 |
| Debt-to-Equity | 0.07-0.7x | 0.17 | 0.24-0.8x | 0.06-1.3x | 0.72+0.4x | N/A | 1.06+0.7x | 1.36 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Telomir Pharmaceuticals, Inc. TELO | FY2025 | N/A | -$10.4M | N/A | $77.3M | — |
| Tempest Therapeutics, Inc. TPST | FY2025 | N/A | -$26.3M | N/A | $10.5M | — |
| PepGen Inc. PEPG | FY2025 | N/A | -$89.7M | N/A | $180.1M | — |
| Acrivon Therapeutics, Inc. ACRV | FY2025 | N/A | -$77.9M | N/A | $70.3M | — |
| Radiopharm Theranostics Limited RADX | FY2025 | $3.6M | -$38.3M | N/A | $15.0M | 20/100 |
| CalciMedica, Inc. CALC | FY2025 | N/A | -$29.6M | N/A | $7.1M | — |
Where Telomir Pharmaceuticals, Inc. Ranks
Frequently Asked Questions
Is Telomir Pharmaceuticals, Inc. profitable?
No, Telomir Pharmaceuticals, Inc. (TELO) reported a net income of -$10.4M in fiscal year 2025.
What is Telomir Pharmaceuticals, Inc.'s return on equity (ROE)?
Telomir Pharmaceuticals, Inc. (TELO) has a return on equity of -176.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Telomir Pharmaceuticals, Inc.'s operating cash flow?
Telomir Pharmaceuticals, Inc. (TELO) recorded an outflow of $3.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Telomir Pharmaceuticals, Inc.'s total assets?
Telomir Pharmaceuticals, Inc. (TELO) had $7.3M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Telomir Pharmaceuticals, Inc. spend on research and development?
Telomir Pharmaceuticals, Inc. (TELO) invested $2.4M in research and development during fiscal year 2025.
What is Telomir Pharmaceuticals, Inc.'s current ratio?
Telomir Pharmaceuticals, Inc. (TELO) had a current ratio of 5.14 as of fiscal year 2025, which is generally considered healthy.
What is Telomir Pharmaceuticals, Inc.'s debt-to-equity ratio?
Telomir Pharmaceuticals, Inc. (TELO) had a debt-to-equity ratio of 0.24 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Telomir Pharmaceuticals, Inc.'s return on assets (ROA)?
Telomir Pharmaceuticals, Inc. (TELO) had a return on assets of -141.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Telomir Pharmaceuticals, Inc.'s P/E ratio?
Telomir Pharmaceuticals, Inc. (TELO) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $77.3M as of Oct 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Telomir Pharmaceuticals, Inc.'s price-to-sales ratio?
Telomir Pharmaceuticals, Inc. (TELO) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $77.3M as of Oct 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Telomir Pharmaceuticals, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Telomir Pharmaceuticals, Inc. (TELO) held $7.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $3.7M over that year. Dividing the one by the other, the reported balance equals about 24 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Telomir Pharmaceuticals, Inc.'s Piotroski F-Score?
Telomir Pharmaceuticals, Inc. (TELO) has a Piotroski F-Score of 2 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Telomir Pharmaceuticals, Inc.'s earnings high quality?
Telomir Pharmaceuticals, Inc. (TELO) reported a net loss of $10.4M while operations used $3.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.